181 related articles for article (PubMed ID: 3455679)
1. Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders.
Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E
Cancer Res; 1986 Feb; 46(2):975-80. PubMed ID: 3455679
[TBL] [Abstract][Full Text] [Related]
2. Antigenic characteristics of circulating granulocyte-macrophage progenitors (CFU-GM) in idiopathic myelofibrosis and polycythaemia vera defined by monoclonal antibodies.
Robak T
Arch Immunol Ther Exp (Warsz); 1989; 37(1-2):17-28. PubMed ID: 2619501
[TBL] [Abstract][Full Text] [Related]
3. Antigenic phenotype of chronic granulocytic leukaemia progenitor cells in chronic phase and in blastic transformation characterized by means of monoclonal antibodies.
Robak T
Arch Immunol Ther Exp (Warsz); 1988; 36(4):471-85. PubMed ID: 3074744
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
5. Antigenic characteristics of erythropoietin dependent and independent erythroid progenitors (BFU-E and CFU-E) in polycythaemia vera and idiopathic myelofibrosis defined by monoclonal antibodies.
Robak T
Arch Immunol Ther Exp (Warsz); 1988; 36(6):733-47. PubMed ID: 3254121
[TBL] [Abstract][Full Text] [Related]
6. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
7. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
8. Expression of myeloid differentiation antigens on normal and chronic granulocytic leukemia erythroid progenitor cells identified by monoclonal antibodies.
Robak T
Arch Immunol Ther Exp (Warsz); 1987; 35(4):519-29. PubMed ID: 3481543
[TBL] [Abstract][Full Text] [Related]
9. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
11. Application of monoclonal antibodies in the antigenic characteristics of normal myeloid progenitor cells and clonogenic blasts in acute myeloid leukaemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1988; 36(1):71-84. PubMed ID: 3233065
[TBL] [Abstract][Full Text] [Related]
12. Endogenous erythroid colony formation in myeloproliferative diseases does not depend on T cells.
Robak T; Hast R; Goldman JM
Exp Hematol; 1986 Mar; 14(3):197-201. PubMed ID: 3485053
[TBL] [Abstract][Full Text] [Related]
13. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
14. [Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases].
Seewann HL
Wien Med Wochenschr Suppl; 1986; 100():1-24. PubMed ID: 3471009
[TBL] [Abstract][Full Text] [Related]
15. Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro.
Maze R; Horie M; Hendrie P; Vadhan-Raj S; Tricot G; Gordon M; Nemunaitis J; Ashman LK; Broxmeyer HE
Exp Hematol; 1993 Apr; 21(4):545-51. PubMed ID: 7681784
[TBL] [Abstract][Full Text] [Related]
16. Staging of leukemic progenitor cells in acute myeloid leukemia by phenotyping with myeloid monoclonal antibodies.
Hast R; Dowding C; Robak T; Goldman JM
Exp Hematol; 1986 Nov; 14(10):981-7. PubMed ID: 3464449
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
18. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
19. Abnormal modulation of granulocyte/macrophage progenitor proliferation by prostaglandin E in chronic myeloproliferative disorders.
Taetle R; Guittard JP; Mendelsohn JM
Exp Hematol; 1980 Nov; 8(10):1190-1201. PubMed ID: 6971757
[TBL] [Abstract][Full Text] [Related]
20. High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival.
Sagaster V; Ohler L; Berer A; Kabrna E; Ofner P; Lechner K; Geissler K
Ann Hematol; 2004 Jan; 83(1):9-13. PubMed ID: 13680175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
